Investors
Oxurion/Investors/News/Oxurion NV Reports Positive Topline Phase 1 Results with …

Oxurion NV Reports Positive Topline Phase 1 Results with THR-149, a novel, potent plasma kallikrein inhibitor for the treatment of DME

1 Jul 2019General

Documents

English
Download PDF

Back to news